PPIAL4E inhibitors are a class of chemical compounds that target the inhibition of the PPIAL4E protein, a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family. These enzymes are known for their role in catalyzing the isomerization of peptide bonds at proline residues, which is a key process in protein folding. The PPIAL4E protein, in particular, has garnered interest due to its structural and functional properties that are integral to the modulation of protein dynamics. Inhibitors of PPIAL4E function by binding to the active site or other regulatory domains, effectively blocking its isomerase activity. This inhibition can have profound effects on the conformational states of proteins, as it interferes with the natural folding pathways that rely on proline isomerization. As such, understanding the chemical interactions between PPIAL4E and its inhibitors provides insight into broader biochemical processes such as signal transduction, protein trafficking, and protein degradation.
The molecular mechanisms by which PPIAL4E inhibitors exert their effects involve intricate non-covalent interactions such as hydrogen bonding, hydrophobic interactions, and van der Waals forces. These inhibitors are often designed to closely mimic the natural substrate of PPIAL4E, allowing them to occupy the enzyme's active site. Some inhibitors may also induce conformational changes in the PPIAL4E enzyme itself, stabilizing inactive forms and preventing its participation in downstream processes that rely on proline isomerization. Through the use of advanced techniques such as X-ray crystallography and NMR spectroscopy, researchers are able to map the precise interactions between PPIAL4E inhibitors and the protein, enabling a deeper understanding of the molecular basis for inhibition. This knowledge can be applied to elucidate the role of PPIAL4E in complex biological systems, providing insights into protein dynamics and the regulation of cellular processes at the molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A binds to the cyclophilin family of proteins and inhibits their peptidyl-prolyl cis-trans isomerase activity, which would lead to the functional inhibition of PPIase A-like 4G by preventing its interaction with substrates. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 (Tacrolimus) binds to FKBP (FK-506 binding protein), inhibiting its isomerase activity, which is analogous to the activity of PPIase A-like 4G, thus potentially inhibiting the isomerase function of the target protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12, a member of the FKBP family, which shares the peptidyl-prolyl isomerase activity with PPIase A-like 4G, and this complex inhibits mTOR, a kinase that is crucial in regulating cell growth and protein synthesis pathways that could be related to the target protein's function. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone engages PPARγ, a nuclear receptor that can regulate gene expression, including genes related to the function of peptidyl-prolyl isomerases, thereby inhibiting the functional activity of PPIase A-like 4G through altered gene expression patterns. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, similar to Pioglitazone, activates PPARγ which can alter the gene expression related to the peptidyl-prolyl isomerase family, potentially resulting in the inhibition of PPIase A-like 4G activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase, which affects pyrimidine synthesis. Since peptidyl-prolyl isomerases are involved in protein folding and function, the reduction in pyrimidine synthesis can indirectly inhibit the function of PPIase A-like 4G. | ||||||